Chondrosarcoma
Symptoms, Doctors, Treatments, Advances & More

Chondrosarcoma Overview

Save information for later
Sign Up

Learn About Chondrosarcoma

View Main Condition: Brain Tumor

What is the definition of Chondrosarcoma?
Chondrosarcoma is a rare, slow-growing form of bone cancer that develops in the bones or the cartilage. The cartilage is the connective tissue from which most bones develop. Chondrosarcomas appear in bones or cartilage at the base of the skull, arms, scapula, ribs, pelvis, knee, femur (thighbone), or tibia.
What are the symptoms of Chondrosarcoma?
Symptoms of chondrosarcoma depend on the cartilage or bone that is involved and include the appearance of a large mass on the affected bone, swelling and pressure surrounding the mass, muscle wasting, gradually increasing pain not relieved with rest, constant pain that worsens at night, and fracture of the affected bone. A chondrosarcoma that appears on the spine may cause weakness, numbness, and an inability to control the release of urine (incontinence) or bowels.
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for Chondrosarcoma?
Treatment for chondrosarcoma depends on a patient’s age, overall health, medical history, the stage and location of the cancer, and may include surgery to remove the tumor, bone reconstructive surgery, amputation, radiation therapy, chemotherapy, and physical therapy.
Who are the top Chondrosarcoma Local Doctors?
Melissa A. Burgess
Elite in Chondrosarcoma
Dr. Melissa A. Burgess
Hematology Oncology
Elite in Chondrosarcoma
Dr. Melissa A. Burgess
Hematology Oncology

UPMC Hillman Cancer Center

5115 Centre Avenue, Hillman Cancer Center, 
Pittsburgh, PA 
412-623-4759
Experience:
17+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Melissa Burgess, MD, is an assistant professor at the University of Pittsburgh School of Medicine and a medical oncologist. She specializes in the treatment of soft tissue and bone sarcomas and Merkel cell carcinoma. Dr. Burgess is rated as an Elite provider by MediFind in the treatment of Chondrosarcoma. Her top areas of expertise are Adult Soft Tissue Sarcoma, Liposarcoma, Merkel Cell Carcinoma, Chondrosarcoma, and Gamma Knife Radiosurgery.

Brian E. Brigman
Elite in Chondrosarcoma
Dr. Brian E. Brigman
Surgical Oncology
Elite in Chondrosarcoma
Dr. Brian E. Brigman
Surgical Oncology

Duke Cancer Center

20 Duke Medicine Cir, 
Durham, NC 
919-681-6900
Experience:
32+ years
Languages Spoken:
English
See accepted insurances

As an orthopaedic oncologist, I am passionate about providing the best diagnostic and therapeutic surgical care for patients with benign or malignant bone or soft tissue tumors of the musculoskeletal system. As the director of the Sarcoma program at the Duke Cancer Institute, my passion is building our team to provide the best clinical care and basic scientific, translational and clinical research to serve our patients. Dr. Brigman is rated as an Elite provider by MediFind in the treatment of Chondrosarcoma. His top areas of expertise are Adult Soft Tissue Sarcoma, Bone Tumor, Chondrosarcoma, Bone Graft, and Hip Replacement.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Chondrosarcoma
Dr. Kevin A. Raskin
Orthopedics
Elite in Chondrosarcoma
Dr. Kevin A. Raskin
Orthopedics

Massachusetts General Physicians Organization Inc

55 Fruit St, 
Boston, MA 
617-724-0287
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Kevin Raskin is an Orthopedics provider in Boston, Massachusetts. Dr. Raskin is rated as an Elite provider by MediFind in the treatment of Chondrosarcoma. His top areas of expertise are Bone Tumor, Adult Soft Tissue Sarcoma, Osteosarcoma, Bone Graft, and Osteotomy.

View All Doctors
What are the latest Chondrosarcoma Clinical Trials?
A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled Study of Ivosidenib in Participants ≥18 Years of Age With Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen
A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled Study of Ivosidenib in Participants ≥18 Years of Age With Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen
Enrollment Status: Recruiting
Publish Date: February 06, 2026
Intervention Type: Drug
Study Phase: Phase 3

Summary: Study CL3-95031-007 (CHONQUER) is a Phase 3, international, multicenter, double-blind, randomized, placebo-controlled study of orally administered ivosidenib. Participants are required to have a histopathological diagnosis consistent with isocitrate dehydrogenase-1 (IDH1) gene-mutated, locally advanced or metastatic conventional chondrosarcoma Grades 1, 2, or 3 and not eligible for curative resect...

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Study to Evaluate the Utilization of 3D Printed Models in Pre-Operative Planning
A Study to Evaluate the Utilization of 3D Printed Models in Pre-Operative Planning
Enrollment Status: Recruiting
Publish Date: February 06, 2026
Intervention Type: Diagnostic test, Device
Study Phase: Not Applicable

Summary: This prospective, multi-center, randomized controlled study aims to assess the efficacy of utilizing 3D printed models in preoperative planning for the excision of tumors involving bony structures within the body. The study is expected to last approximately 12 months and involve up to 150 subjects across up to 5 sites. Subjects will be randomized in a 1:1 ratio into either the experimental arm, ut...

View All Clinical Trials